Tested compounds/extract IC50 (Mean ± S.E.)
HCT116 HEP2 MCF7 HELA HEPG2
MEP 4.36 ± 0.32 4.99 ± 0.36 6.56 ± 0.32 4.90 ± 0.21 2.14 ± 0.35
S1 2.97 ± 0.38 3.43 ± 0.49 2.97 ± 0.29 3.43 ± 0.50 2.51 ± 0.21
S2 2.23 ± 0.35 12 ± 0.79 2.36 ± 0.41 13.4 ± 1.55 2.12 ± 0.90
S3 5.20 ± 0.70 11.2 ± 0.69 4.51 ± 0.21 10.01 ± 0.21 3.52 ± 0.21
S4 2.97 ± 0.57 3.13 ± 0.26 3.13 ± 0.11 2.97 ± 0.22 2.67 ± 0.44
S5 6.79 ± 1.41 6.94 ± 0.27 8.46 ± 0.45 9.07 ± 0.41 4.34 ± 0.31
Doxorubicin® 0.69 ± 0.21 1.10 ± 0.30 0.7 ± 0.12 0.91 ± 0.10 0.67 ± 0.21
MEP: Methanol Extract of S. melongena peels; HCT116: Colon cancer cell line; HEP2: Lung cancer cell line; MCF7: Breast cancer cell line; HELA: Cervix cancer cell line; HEPG2: Liver cancer cell line; SD: Standard error for n = 3
Table 3: In vitro anticancer effect of MEP and the isolated compounds